T cell-based therapies for atherosclerosis

Area of Science:

• Immunology
• Cardiovascular Research
• Atherosclerosis Pathogenesis

Background:

• Cardiovascular diseases (CVDs) are leading causes of death, primarily driven by atherosclerosis.
• Atherosclerosis is a chronic inflammatory process involving cholesterol accumulation and immune cell responses in artery walls.
• T cells play a critical role in both promoting and inhibiting atherosclerotic plaque development.

Purpose of the Study:

• To review experimental and pre-clinical studies on manipulating cellular immunity for atherosclerosis treatment.
• To examine the dual role of T cells, including effector T cells and regulatory T cells (Tregs), in atherosclerosis.
• To assess the potential of T cell-based therapies in managing cardiovascular disease risk.

Main Methods:

• Review of experimental and pre-clinical studies focusing on cellular immunity manipulation in atherosclerosis.
• Analysis of therapeutic strategies including vaccination, antibody therapies, dendritic cell-based therapies, and metabolite-based interventions.
• Evaluation of T cell modulation effects on atherosclerotic plaque progression in animal models.

Main Results:

• T effector cells are implicated in aggravating atherosclerosis, while regulatory T cells (Tregs) demonstrate inhibitory effects on inflammation and lesion formation.
• T cell mediators can influence systemic lipid metabolism, impacting overall cardiovascular disease risk.
• Various T cell modulation strategies, including vaccination and antibody therapies, have shown benefits in reducing atherosclerotic plaque progression in animal studies.

Conclusions:

• Modulating T cell responses presents a promising avenue for combating atherosclerosis and cardiovascular diseases.
• Therapeutic strategies targeting T cells have demonstrated significant potential in pre-clinical models.
• Further clinical investigation is required to establish the efficacy of T cell-based therapies in human patients.